Baillie Gifford & Co
MESO

Baillie Gifford & Co’s Mesoblast MESO Stock Holding History

Baillie Gifford & Co’s Portfolio MESO Stock Details MESO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-67,800
Closed -$863K – 198
2015
Q4 		$863K Buy
+67,800
New +$829K ﹤0.01% 181

Other funds holding MESO

PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OWD
Osborn Williams & Donohoe Cincinnati, Ohio $762M AUM 2.74% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baillie Gifford & Co's MESO Position: Q1 2016 in Review

Baillie Gifford & Co sold out of Mesoblast (MESO) in Q1 2016, closing a stake of 67,800 shares — an estimated $863K sold.

Baillie Gifford & Co first reported a position in MESO in Q4 2015 and held it in 1 quarter. The position peaked at $863K in Q4 2015. 17 funds tracked by Wall St. Rank hold MESO as of Q1 2016.

  • Baillie Gifford & Co reported no remaining Mesoblast position as of Q1 2016 after selling out during the quarter.
  • Baillie Gifford & Co sold 67,800 Mesoblast shares in Q1 2016, an estimated $863K.
  • Baillie Gifford & Co first reported a position in Mesoblast in Q4 2015 and held it in 1 quarter.
  • Baillie Gifford & Co's Mesoblast position peaked at $863K in Q4 2015.
  • 17 funds tracked by Wall St. Rank held Mesoblast as of Q1 2016.

Based on Baillie Gifford & Co's 13F filing for Q1 2016, filed 5 May 2016.